Market OutlookAccording to this research’s research, the global human microbiome market is expected to grow with 21.89% of CAGR for the estimated period of 2019-2027.The microbiome is a term used to describe the genes of various microbes like bacteria, fungi, protozoa and viruses that live on and in the human body. The human body hosts numerous species of microscopic organisms, and the majority of microbes lives chiefly in the human gut. The growth of the global human microbiome market owes to the rising human microbiome-based drugs and diagnostics tools used in treating various diseases. The sector provides vast opportunities for biotechnology, pharmaceuticals and diagnostics companies, thereby forecast a bright prospect.The factors like growing prevalence for technological drug development like precision medicines and rising emphasis on early diseases detection and diagnosis drives the adoption rate of human microbiomes. Also, the global rise of chronic diseases like cancer, cardiovascular diseases, diabetes and others pushes the need for early disease detection and diagnosis, which further drives the human microbiome adoption for therapeutics. Furthermore, the rising investments by government organizations and private firms for disease detection, diagnosis and treatments are boosting the growth of the human microbiome market.Though numerous elements drive the market, many restraints and challenges hinder the growth. Lack of awareness, technological expertise and skilled professionals pose significant limitations, eventually curbing the growth of the human microbiome market.Regional OutlookThe human microbiome market is segmented among regions such as North America, Europe, Asia- Pacific, and Rest of World. The North America human microbiome market is surging owing to rising investments, funding and R&D activities by companies, research institutes and other organizations. On the other hand, the Europe market is flourishing as a result of growing initiatives by central government in research and development along with establishments of startups. Also, the growing funding in precision medicines and development of human microbiome drives the Asia-Pacific microbiomes market.Competitive OutlookThe prominent players operating in the global market are Actogenix N.V., 4D Pharma, Enterome SA, Microbiome therapeutics, Miomics, Rebiotix, Second Genome, Symbiotix Biotherapies Inc., Avidbiotics Inc., Metabiomics, Vedanta Biosciences Inc. Avidbiotics Corporation, Metabogen AB, Osel Inc., Symberix Inc., and Ritter Pharmaceuticals Inc.The number of key players in the global market is limited. However, as a result of large funding from investors and encouragement for research activities from governments, many new players are entering the market.
Table of Contents
1. Global Human Microbiome Market- Summary
2. Industry Outlook
3. Human Microbiome Industry Outlook - By Products
4. Human Microbiome Industry Outlook - By Applications
5. Human Microbiome Industry Outlook - By Diseases
6. Human Microbiome Industry – Regional Outlook
7. Competitive Landscape
8. Methodology & Scope
Table List
Figures List
Companies Mentioned
A selection of companies mentioned in this report includes:
- Pharma
- Avidbiotics Inc.
- Actogenix N.V. (Acquired by Intrexon Corporation)
- Avidbiotics Corp.
- Enterome SA
- Metabiomics
- Microbiome Therapeutics
- Metabogen AB
- Miomics
- Osel Inc.
- Rebiotix
- Ritter Pharmaceuticals, Inc.
- Second Genome
- Symberix Inc.
- Symbiotix Biotherapies, Inc.
- Vedanta Biosciences, Inc. (Acquired by Puretech Health Plc)
Methodology
LOADING...